CONMED Corporation (CNMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CONMED Corporation (CNMD) Healthcare & Pipeline Overview

CONMED Corporation, a medical technology company, specializes in surgical devices and equipment, offering orthopedic and general surgery solutions. With a focus on minimally invasive procedures and a direct-to-hospital sales model, CONMED serves a global market, maintaining a competitive position through product innovation and established brands.

What Is the Investment Thesis for CNMD?

CONMED Corporation presents a compelling investment case due to its established position in the medical devices market and its focus on surgical solutions. With a market capitalization of $1.54B and a P/E ratio of 20.3, CONMED demonstrates financial stability. The company's gross margin of 53.6% indicates efficient operations and strong pricing power. Growth catalysts include continued innovation in orthopedic and general surgery products, expansion into emerging markets, and strategic acquisitions. Key value drivers are the increasing demand for minimally invasive surgical procedures and the aging global population. Potential risks include competition from larger medical device companies and regulatory changes in the healthcare industry. The company's dividend yield of 1.09% provides a modest return for investors.

Based on FMP financials and quantitative analysis

CNMD Key Highlights

Market Cap of $1.54B reflects CONMED's established position in the medical devices market.

• P/E Ratio of 20.3 indicates a reasonable valuation compared to its earnings.
• Gross Margin of 53.6% demonstrates efficient operations and strong pricing power in the surgical devices market.
• Dividend Yield of 1.09% provides a modest return for investors.
• Beta of 0.99 suggests the stock's volatility is similar to the overall market.

Who Are CNMD's Competitors?

CNMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CNMD's Key Strengths?

Established brands in orthopedic and general surgery.

• Proprietary technologies and innovative products.
• Direct sales force and distribution network.
• Strong relationships with surgeons and healthcare providers.

What Are CNMD's Weaknesses?

Smaller market capitalization compared to major competitors.

• Reliance on specific surgical solutions.
• Potential vulnerability to pricing pressures.
• Limited geographic diversification.

What Could Drive CNMD Stock Higher?

New product launches in orthopedic surgery segment.

• Expansion of sales and marketing efforts in emerging markets.
• Strategic acquisitions to broaden product portfolio.
• Development and commercialization of advanced endoscopic technologies.

What Are the Key Risks for CNMD?

Increased competition from larger medical device companies.

• Regulatory changes in the healthcare industry.
• Pricing pressures from hospitals and healthcare providers.
• Product liability claims.
• Dependence on key suppliers for critical components.

What Are the Growth Opportunities for CNMD?

• Expansion of Orthopedic Surgery Product Line: CONMED has the opportunity to further expand its orthopedic surgery product line, focusing on innovative solutions for soft tissue repair and minimally invasive procedures. The global orthopedic devices market is projected to reach $54.2 billion by 2028, presenting a significant growth opportunity. By investing in research and development and strategic acquisitions, CONMED can capture a larger share of this market and drive revenue growth. Timeline: Ongoing.
• Penetration of Emerging Markets: CONMED can drive growth by expanding its presence in emerging markets, where healthcare spending is increasing and demand for advanced surgical solutions is rising. These markets offer significant potential for revenue growth. CONMED can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets effectively. Timeline: Ongoing.
• Strategic Acquisitions: CONMED can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to innovative technologies. The medical devices industry is characterized by consolidation, and acquisitions can provide CONMED with a competitive advantage. By carefully selecting acquisition targets, CONMED can enhance its growth prospects and create shareholder value. Timeline: Ongoing.
• Development of Endoscopic Technologies: CONMED can focus on developing and commercializing advanced endoscopic technologies for gastroenterology procedures and the treatment of biliary structure diseases. The global endoscopy devices market is projected to reach $41.2 billion by 2027, presenting a significant growth opportunity. By investing in research and development and strategic partnerships, CONMED can capture a larger share of this market. Timeline: Ongoing.
• Increased Adoption of Minimally Invasive Surgery: The increasing adoption of minimally invasive surgical procedures is driving demand for CONMED's products. Minimally invasive surgery offers several benefits, including reduced pain, shorter hospital stays, and faster recovery times. By focusing on developing and marketing products that support minimally invasive surgery, CONMED can capitalize on this trend and drive revenue growth. Timeline: Ongoing.

What Are CNMD's Competitive Advantages?

• Established brands (Hall, CONMED Linvatec, Concept, Shutt).
• Proprietary technologies in orthopedic and general surgery.
• Direct sales force and distribution network.
• Strong relationships with surgeons and healthcare providers.

What Does CNMD Do?

CONMED Corporation, incorporated in 1970 and headquartered in Largo, Florida, is a global medical technology company focused on the development, manufacturing, and sale of surgical devices and related equipment. The company's origins lie in addressing the evolving needs of surgeons and healthcare providers by offering innovative solutions for a range of surgical procedures. Over the years, CONMED has expanded its product portfolio through internal development and strategic acquisitions, establishing itself as a key player in the medical devices market. CONMED's product offerings are divided into two main categories: orthopedic surgery and general surgery. The orthopedic surgery segment includes products like the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, designed to aid in the repair of soft tissue injuries. These products are marketed under the Hall, CONMED Linvatec, Concept, and Shutt brands. The general surgery segment includes products for clinical insufflation, smoke evacuation, electrosurgical procedures, and endomechanical applications. Additionally, CONMED offers endoscopic technologies for gastroenterology procedures and products for treating biliary structure diseases, along with cardiac monitoring products like ECG and EEG electrodes and defibrillation pads. CONMED distributes its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors, ensuring broad market access and customer reach.

What Products and Services Does CNMD Offer?

• Develops surgical devices and related equipment.
• Manufactures surgical devices for orthopedic and general surgery.
• Sells surgical devices and equipment to hospitals and surgery centers.
• Offers orthopedic surgery products for soft tissue repair.
• Provides general surgery products for clinical insufflation and smoke evacuation.
• Markets endoscopic technologies for gastroenterology procedures.
• Offers cardiac monitoring products, including ECG and EEG electrodes.

How Does CNMD Make Money?

• Develops and manufactures surgical devices.
• Sells products directly to hospitals and surgery centers.
• Utilizes medical specialty distributors for market reach.
• Focuses on both orthopedic and general surgery solutions.

What Industry Does CNMD Operate In?

CONMED Corporation operates within the global medical devices industry, which is characterized by continuous innovation, increasing demand for minimally invasive procedures, and an aging global population. The industry is highly competitive, with major players like Johnson & Johnson, Medtronic, and Stryker dominating the market. CONMED differentiates itself through its focus on specific surgical solutions and its established brands. The medical devices industry is expected to continue growing, driven by technological advancements and increasing healthcare spending. CONMED's strategic focus on orthopedic and general surgery positions it well to capitalize on these trends.

Who Are CNMD's Key Customers?

• Hospitals
• Surgery centers
• Healthcare institutions

Company Profile

CONMED Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Largo, US. The company is led by CEO Patrick J. Beyer. CNMD has traded publicly since 1987.

Return on equity for CONMED Corporation stands at 5.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.4%, showing how much profit it generates from its asset base. CNMD trades at a trailing price-to-earnings ratio of 20.27, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 12.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.5%, the inverse of the P/E and a quick read on earnings relative to price.

CNMD Valuation & Market Position

With a $1.54B market cap, CONMED Corporation sits in the small-cap segment of the market. Relative to its peer group, CNMD's quantitative score of 76/100 is roughly in line with the peer average of 81/100.

Quarterly Financial Performance: CONMED Corporation

Revenue for CONMED Corporation came in at $343.5M during Q2 2026, a 8.3% improvement versus the preceding quarter. The company recorded net income of $23.1M, with diluted EPS of $0.77. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CNMD averaged $0.46 in diluted EPS.

CONMED Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.99 places it in the grey zone, a middle ground that warrants monitoring.

CONMED Corporation has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 10.1% above estimates on average.

Wall Street analysts project CONMED Corporation revenue of about $1.37B for fiscal 2026, with EPS near $4.54. The estimate reflects 5 contributing analysts.

CNMD Financials

CNMD Latest News

CNMD Analyst Consensus

CNMD MoonshotScore

CNMD Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources